Cardiosipin - instructions for use, dose, side effects, contraindications

Cardioksipin inhibits platelet aggregation, reduces the overall coagulation index, prolongs the clotting time. Stabilizes the membranes of cells of blood vessels and erythrocytes, increases the resistance of red blood cells to mechanical trauma and hemolysis. It has angioprotective properties. Improves microcirculation. Effectively inhibits free radical oxidation of lipids of biomembranes, increases the activity of antioxidant enzymes. Stabilizes cytochrome P-450, has an antitoxic effect. In extreme situations, accompanied by increased lipid peroxidation and hypoxia, it optimizes bioenergetic processes.Cardiocipine reduces the signs of cerebral hemodysfunction. Increases brain resistance to hypoxia and ischemia. With violations of cerebral circulation (ischemic and hemorrhagic) contributes to the correction of vegetative dysfunctions, facilitates the restoration of integrative activity of the brain, improves mnestic functions.

The drug has a pronounced cardioprotective effect. Expands coronary vessels, reduces ischemic damage to the myocardium. With myocardial infarction limits the magnitude of the focus of necrosis, accelerates reparative processes, contributes to the normalization of myocardial metabolism. Has a beneficial effect on the clinical course of myocardial infarction, reducing the incidence of acute heart failure. Promotes regulation of the oxidation-reduction system in case of circulatory failure.

Pharmacokinetics:

When administered intravenously at a dose of 10 mg / kg, a low period of hemelimination was noted (T_1/2 - 18 min, which indicates a high rate of elimination of the drug from the blood). The value of the elimination constant is 0.041 min; total clearance C1 - 214.8 ml / min; apparent volume of distribution. - 5.2 liters.The drug quickly penetrates into the organs and tissues, where it is deposited and metabolized. Metabolites of methyl ethylpyridinol, represented by dealkylated and conjugated products of its transformation, were detected. Methylethylpyridinol metabolites are excreted by the kidneys. In significant quantities, 2-ethyl-6-methyl-3-hydroxypyridine phosphate is found in the liver.

In pathological conditions, for example, in the case of coronary occlusion, the pharmacokinetics of methyl ethyl pyridinol change. Decreased rate of excretion, resulting in increased bioavailability of the drug. The time of methylethylpyridinol residence in the bloodstream increases, which may be due to its return from the depot, including ischemic myocardium.

Indications:

In neurology and neurosurgery: hemorrhagic stroke recovery period, ischemic stroke, transient ischemic attacks, chronic cerebral circulatory insufficiency, traumatic brain injury, accompanied by cerebral injuries; postoperative period in patients with traumatic brain injury, surgery for epi-, subdural and intracerebral hematomas, combined with brain injuries.

In cardiology: acute myocardial infarction, prevention of "reperfusion syndrome", unstable angina.

Contraindications:The use of the drug is contraindicated for individual intolerance, in children under 18 years (due to lack of data).

Carefully:Patients with hemostasis disorder, during surgical operations or patients with symptoms of severe bleeding (due to the effect on platelet aggregation).

Pregnancy and lactation:The use of the drug during pregnancy and during breastfeeding is contraindicated (efficacy and safety not established).

Dosing and Administration:

In neurology and neurosurgery solution of Cardiocipine for infusions are used intravenously drip in a daily dose of 10 mg / kg (2 ml / kg) for 10-12 days. Enter at a speed of 20-30 drops per minute. Subsequently, 2-10 ml of a 3% solution of Cardiocipine are switched to intramuscular injections 2-3 times a day for 20 days.

In cardiology begin with an intravenous drip (20-40 drops per minute), administering 120-180 ml of the drug (600-900 mg of methyl ethyl pyridinol) 1-3 times a day for 5-15 days depending on the course of the disease, followed by a transition to intramuscular injection of 2 -10 ml of a 3% solution of Cardiocipine 2-3 times a day for 10-30 days.

Side effects:In some cases, excitement (short-term), drowsiness, increased blood pressure, local reactions in the area of administration (transient burning sensation, itching, pain), headache, pain in the heart, allergic reactions (itching, rash, reddening of the skin) are noted. People with chronic pathology of the digestive system may experience nausea, unpleasant sensations in the stomach.

Overdose:

Symptoms: increased side effects of the drug (the emergence of drowsiness and sedation), a short-term increase in blood pressure.

Treatment: symptomatic, incl.ch. the appointment of antihypertensive drugs under the control of blood pressure. There is no specific antidote.

Interaction:

α-Tocopherol acetate potentiates the antioxidant effect of cardiocipine.

Cardiocipine should not be mixed with other injections in one syringe.

Special instructions:It is necessary during the treatment to constantly monitor blood pressure and clotting.

Effect on the ability to drive transp. cf. and fur:Persons who report drowsiness or changes in blood pressure after using the drug,should refrain from driving and potentially dangerous machinery. Do not apply during work drivers of vehicles.

Form release / dosage:Solution for infusions 5 mg / ml.

Packaging:

100 or 200 ml in a bottle with a glass, corked rubber stopper and crimped aluminum cap.

Each bottle, together with instructions for use, is placed in a pack of cardboard.

56 bottles of 100 ml or 24 bottles of 200 ml with instructions for use on the number of bottles are placed in a group package - boxes (with gaskets and grills) made from corrugated cardboard.

Storage conditions:

In dry, dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

2 years.

Do not use after the expiration date.

Terms of leave from pharmacies:On prescription

Registration number:LSR-002135/08

Date of registration:27.03.2008 / 30.04.2015

Expiration Date:Unlimited

The owner of the registration certificate:BIOSINTEZ, PAO BIOSINTEZ, PAO Russia

Manufacturer: & nbsp

BIOSINTEZ, PAO Russia

Information update date: & nbsp10.12.2017

Illustrated instructions

Instructions

Cardiocipine (Cardioxipin)